Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB26FYM55
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,347
Award facts
- Contract value 100% obligated
- $14,346.99 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,346.99 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support the Department of Defense's pharmaceutical supply requirements globally.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical supplier within the federal pharmaceutical supply chain, with numerous delivery orders issued by the Defense Logistics Agency between October and November 2025 covering a diverse product portfolio including oncology treatments, biologics, vaccines, and specialty pharmaceuticals. The company's role under the PPV-G GEN V program positions it as a regional prime vendor contractor authorized to supply a comprehensive range of pharmaceutical products and medical consumables to military healthcare facilities worldwide. With a 30-month base period and three 30-month option periods extending through December 31, 2036, the underlying Indefinite Delivery Contract provides a framework with a ceiling value of $499,999,999 to support recurring medical supply needs across the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DB26FYM55?
SPE2DB26FYM55 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FYM55 worth?
The government has obligated $14,347 on SPE2DB26FYM55.
Is contract SPE2DB26FYM55 an order under another contract?
Yes. SPE2DB26FYM55 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM55 competed?
The extent of competition for SPE2DB26FYM55 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award